Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-01-2021 | Acute Myeloid Leukemia | Original Article

Prognostic Impact of Serum Growth Differentiation Factor 15 Level in Acute Myeloid Leukemia Patients

Authors: Hany Mohamed Hegab, Amro Mohamed Sedky El-Ghammaz, Mostafa Kamal El-Razzaz, Reham Ali Ali Helal

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2021

Abstract

Growth differentiation factor 15 (GDF15) plays an important role in cancer pathophysiology and prognosis. However, limited studies analyzed its level and prognostic value in acute myeloid leukemia (AML) patients. This study included 56 adult AML patients. Serum GDF15 level was measured at diagnosis in all patients by enzyme-linked immunosorbent assay. Remission and survival statuses were assessed at 90 days following treatment. GDF15 level was significantly higher in patients than in controls (P < 0.001). GDF15 level correlated positively with age (P < 0.001), hemoglobin level (P = 0.027), and platelet count (P = 0.024). High GDF15 above the median level was associated with inferior OS (P = 0.044) together with high platelet count (P = 0.006) and high bone marrow blast percent (P = 0.038). There was no statistically significant difference between patients with GDF15 above and below the median level regarding DFS (P = 0.881). On multivariate analysis for OS, GDF15 level was an independent risk factor (P = 0.047). In conclusion, serum GDF15 level is significantly elevated in AML patients and high GDF15 level is associated with inferior OS.

Bootcov MR, Bauskin AR, Valenzuela SM et al (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-superfamily. Proc Natl Acad Sci USA 94:11514–11519PubMed

Berezin AE (2016) Diabetes mellitus related biomarker: the predictive role of growth-differentiation factor-15. Diabetes Metab Syndr 10(1 Suppl. 1):S154–S157PubMed

Breit SN, Johnen H, Cook AD et al (2011) The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29:187–195PubMed

Mimeault M, Batra SK (2010) Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 224:626–635PubMedPubMedCentral

Buendgens L, Yagmur E, Bruensing J et al (2017) Growth differentiation factor-15 is a predictor of mortality in critically ill patients with sepsis. Dis Markers 2017:5271203PubMedPubMedCentral

Saultz JN, Garzon R (2016) Acute myeloid leukemia: a concise review. J Clin Med 5(3):33PubMedCentral

Döhner K, Döhner H (2008) Molecular characterization of acute myeloid leukemia. Haematologica 93(7):976–982PubMed

Schlenk RF, Döhner H (2013) Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2013:324–330

Uchiyama T, Kawabata H, Miura Y et al (2015) The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis. Cancer Med 4(10):1558–1572PubMedPubMedCentral

10.

Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33(4):451–458

11.

Slovak ML, Kopecky KJ, Cassileth PA et al (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96(13):4075–4083PubMed

12.

Yates J, Glidewell O, Wiernik P et al (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60(2):454–462PubMed

13.

Mayer RJ, Davis RB, Schiffer CA et al. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331(14):896–903

14.

Burnett AK, Russell NH, Hills RK et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML 15 trial. J Clin Oncol 31(27):3360–3368PubMed

15.

Medeiros BC (2018) Interpretation of clinical endpoints in trials of acute myeloid leukemia. Leuk Res 68:32–39PubMed

16.

Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE (2001) Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59(4):901–908PubMed

17.

Liu T, Bauskin AR, Zaunders J et al (2003) Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63(16):5034–5040PubMed

18.

Kadara H, Schroeder CP, Lotan D, Pisano C, Lotan R (2006) Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of its role in apoptosis. Cancer Biol Ther 5(5):518–522PubMed

19.

Brown DA, Breit SN, Buring J et al (2002) Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: A nested case-control study. Lancet 359:2159–2163PubMed

20.

Lankeit M, Kempf T, Dellas C et al (2008) Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 177:1018–1025PubMed

21.

Brown DA, Moore J, Johnen H et al. (2007) Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis. A potential marker of erosive joint destruction. Arthritis Rheum 56:753–764PubMed

22.

Breit SN, Carrero JJ, Tsai VW et al (2012) Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant 27:70–75PubMed

23.

Tanno T, Bhanu NV, Oneal PA et al (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13:1096–1101PubMed

24.

Tamary H, Shalev H, Perez-Avraham G et al (2008) Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 112:5241–5244PubMedPubMedCentral

25.

Ramirez JM, Schaad O, Durual S et al (2009) Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol 144:251–262PubMed

26.

Zhang L, Yang X, Pan H-Y et al (2009) Expression of growth differentiation factor 15 is positively correlated with histopathological malignant grade and in vitro cell proliferation in oral squamous cell carcinoma. Oral Oncol 5:627–632

27.

Boyle GM, Pedley J, Martyn AC et al (2009) Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 129:383–391PubMed

28.

Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J (2018) Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass. Cancer Biomark 21(3):505–511PubMed

29.

Lima CA, Jammal MP, Martins-Filho A et al (2018) Stromal growth differentiation factor 15 and its association with ovarian cancer. Gynecol Obstet Invest 83(1):35–39PubMed

30.

Moore AG, Brown DA, Fairlie WD et al (2000) The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 85:4781–4788PubMed

31.

Segerer SE, Rieger L, Kapp M et al (2012) MIC-1 (a multifunctional modulator of dendritic cell phenotype and function) is produced by decidual stromal cells and trophoblasts. Hum Reprod 27(1):200–209PubMed

32.

Lu W, Wan Y, Li Z et al (2018) Growth differentiation factor 15 contributes to marrow adipocyte remodeling in response to the growth of leukemic cells. J Exp Clin Cancer Res 37(1):66PubMedPubMedCentral

33.

Zhai Y, Zhang J, Wang H et al (2016) Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells. J Exp Clin Cancer Res 35(1):147PubMedPubMedCentral

34.

Tarkun P, Mehtap O, Atesoglu EB, Geduk A, Musul MM, Hacihanefioglu A (2013) Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. Eur J Haematol 91:228–235PubMed

35.

Zhao N, Yang J (2014) Expression of serum GDF15 and its clinical significance in multiple myeloma patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban 39(3):270–275PubMed

36.

Corre J, Hébraud B, Bourin P (2013) Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med 2(12):946–952PubMedPubMedCentral

37.

Corre J, Labat E, Espagnolle N et al (2012) Bioactivity of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res 72(6):1395–1406PubMed

38.

Tarkun P, Birtas Atesoglu E, Mehtap O, Musul MM, Hacihanefioglu A (2014) Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients. Acta Haematol 131(3):173–178PubMed

39.

Li C, Wang X, Casal I et al (2016) Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med 20(8):1420–1426PubMedPubMedCentral

40.

Winand FJ, Boegemann M, Gallitz I et al (2014) GDF15 and Hepcidin as prognostic factors in patients with prostate cancer. J Mol Biomark Diagn 5:6

41.

Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B (2010) Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 118(3):237–243PubMed

42.

Lerner L, Hayes TG, Tao N et al (2015) Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients. J Cachexia Sarcopenia Muscle 6(4):317–324PubMedPubMedCentral

Title: Prognostic Impact of Serum Growth Differentiation Factor 15 Level in Acute Myeloid Leukemia Patients
Authors: Hany Mohamed Hegab
Amro Mohamed Sedky El-Ghammaz
Mostafa Kamal El-Razzaz
Reham Ali Ali Helal
Publication date: 01-01-2021
Publisher: Springer India
Keyword: Acute Myeloid Leukemia
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 1/2021
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-020-01315-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study

Primary Mediastinal B Cell Lymphoma: A Limited Institutional Experience with Uniform DAEPOCH-R Protocol

Sitosterolemia: Four Cases of an Uncommon Cause of Hemolytic Anemia (Mediterranean Stomatocytosis with Macrothrombocytopenia)

Does Development of Plasmacytosis have a Role in Spontaneous Remission of Acute Myeloid Leukemia?

Changes in Complement Levels and Activity of Red Blood Cells, Fresh Frozen Plasma, and Platelet Concentrates During Storage

Indian Society of Hematology and Blood Transfusion (ISHBT) Consensus Document on Hematological Practice During COVID-19 Pandemic

Keynote webinar | Spotlight on antibody–drug conjugates in cancer